53 results about "Chikungunya" patented technology

The invention provides a bacillus thuringiensis strain, a fermentation culture method and application of the bacillus thuringiensis strain. The strain is preserved in the China Center for Type Culture Collection on September 28, 2011, the preservation address is No. 299 on eight road, Wuchang District, Wuhan City, Hubei Province, the preservation number is CCTCC No: M 2011334, and the preservation date is September 28, 2011. The strain cultured by the fermentation method has efficient, specific and stable insecticidal activity on culex, aedes and other mosquitoes, has the advantages of low preparation cost, environmental friendliness and the like, can be developed into a biological insecticide for preventing and killing mosquitoes and preventing and controlling malaria, dengue fever, chikungunya and other mosquito-borne infectious diseases, and meets the requirements of green and safe prevention and control in China.

The invention discloses a primer combination and a kit for detecting arbo viruses and application of the primer combination and the kit. The primer combination comprises a specific primer pair for detecting the dengue virus, a specific primer pair for detecting the Zika virus and a specific primer pair for detecting the Chikungunya virus. The primer combination has the characteristics of high sensitivity, good repeatability and strong specificity, and can be used for specifically detecting dengue virus, Zika virus and Chikungunya virus.

The invention belongs to the field of molecular biological detection, and particularly relates to combined nucleic acid detection of three typical mosquito-borne arthroviruses, namely, dengue virus, Zika virus and Chikungunya virus, and four serotypes of the dengue virus are typed by using a melting curve matched molecular beacon design method. The method specifically comprises the following steps: distinguishing and detecting three typical mosquito-borne arbo viruses by using an amplification curve, and marking pathogens in each tube on different probes by using different fluorophores so as to distinguish amplification signals. A melting curve is used for distinguishing four different types of viruses of the dengue virus, and Tm value characteristic peak signals are distinguished by combining a molecular beacon and a locked nucleic acid probe aiming at each type of specific target. According to the invention, clinical differential diagnosis of the three viruses is facilitated, and an auxiliary means is provided for guiding medication for different clinical manifestations in dengue virus typing detection.

The invention discloses a chikungunya virus envelope E2 protein monoclonal antibody and application thereof, and belongs to the technical field of medicines. The chikungunya virus envelope protein E2 expressed by human embryo kidney 293 cells is used as an antigen to immunize a rabbit, B cells capable of being specifically combined with the chikungunya virus envelope protein E2 are screened from rabbit spleen cells through flow sorting, and signal peptide and variable region gene fragments of an antibody are cloned through reverse transcription-polymerase chain reaction. According to the present invention, the chikungunya virus-resistant monoclonal antibody with high neutralizing activity and capable of 100% protection of mice against chikungunya virus lethal attack is obtained by carrying out enzyme-linked immunosorbent assay, in-vitro virus neutralization and mouse toxicity attack experiment after mammalian cell expression and purification, and the recombinant chikungunya virus-resistant monoclonal antibody has characteristics of high neutralizing activity and high immunogenicity, and can be used for preparing the chikungunya virus-resistant monoclonal antibody, and the recombinant chikungunya virus-resistant monoclonal antibody. The monoclonal antibody has application value in prevention and treatment of yellow fever.

The invention belongs to the technical field of biological detection, and relates to a Chikungunya virus detection kit and a detection method. The kit is based on the principle of PCR detection and comprises a primer pair, the sequence of a forward primer of the primer pair is shown as SEQ ID NO: 1, and the sequence of a reverse primer of the primer pair is shown as SEQ ID NO: 2. The chikungunya virus detection kit and the detection method can realize rapid, sensitive and specific detection of chikungunya virus based on the principle of PCR detection, and are especially suitable for various application scenes such as clinical samples, human or animal samples, environmental samples, scientific research samples and the like.

This invention discloses a chikungunya virus genome fragment armored RNA reference, its preparation method, and its application. The preparation process involves the following steps: (1) constructing the prokaryotic expression backbone vector pACYCAR; (2) cloning the CKV genome fragment CKA (nt17-2276); (3) constructing the prokaryotic expression vector pACYCAR-CKA; (4) inducing the expression of armored RNA; and (5) purifying the armored RNA. This invention solves the technical problems of high biosafety risk, poor stability, and insufficient gene fragment coverage in existing CKV nucleic acid detection references. It fills the gap in the lack of high-quality references for CKV detection.

This invention provides the application of apatinib in the preparation of antiviral drugs, specifically involving the application of the anticancer drug apatinib in inhibiting the replication of Hantanensis virus (HTNV) and Chikungunya virus (CHIKV). Apatinib can significantly inhibit HTNV replication and reduce viral titers at the cellular level. Experiments have shown that after treatment with apatinib, the expression levels of viral structural proteins, the nucleic acid levels of HTNV, and the viral titers in the cell culture supernatant were significantly reduced in HTNV-infected A549 cells, while the drug exhibited low cytotoxicity. Furthermore, apatinib can also inhibit CHIKV replication. This invention provides a novel anti-HTNV candidate drug and offers insights for the rapid development of antiviral drugs.

The present disclosure provides neutralising human antibodies that binds to an alphavirus. The antibodies are raised against the chikungunya (CHIKV) virus, and show cross-neutralisation and in vivo protection of other alphaviruses.

The invention discloses a Chikungunya thermal seasonal propagation risk assessment method and system based on a coupling model. The method comprises the following steps: acquiring basic data and preprocessing the basic data; model parameters are divided into a fixed type and a dynamic type, the dynamic parameters are combined with environmental data to calculate and assign values, historical epidemic situation data in the past three years are used as target values, key parameters are adjusted through a least square method, and the error between a model simulation epidemic situation curve and an actual observation value is minimized. Based on the influence of a standardized meteorological data quantification environment on mosquitoes, generating a day-by-day key parameter sequence and inputting the day-by-day key parameter sequence into a medium module; the age structure model is used for simulating population dynamics of mosquitoes at all stages, and the SEI model is used for simulating transmission of viruses in the mosquitoes. The number of infectious mosquitoes output by the medium module is used as a drive, crowd state conversion is simulated through an SEIR model, and the number of infected people every day and the morbidity are obtained; and risk level assessment of the assessment area is completed, and quantitative data support is provided for risk assessment.

The application discloses a kind of diaromatic pyrimidine compounds containing fused heterocycle and preparation method and application thereof.The compound has the structure shown in general formula I.The application further relates to pharmaceutical compositions containing the compound of formula I.Active screening experiments show that the compound of the application has good anti-HIV and CHIKV activity, and therefore the application further provides the use of the above-mentioned compound in the preparation of anti-AIDS drugs and anti-Chikungunya virus drugs.

This application relates to the field of biomedical detection technology, specifically to a combination of biomarkers for assessing the severity of viremia in Chikungunya virus patients and its application. The combination of biomarkers for assessing the severity of viremia in Chikungunya virus patients includes one or more of the following biomarkers: TAP1, ISG15, CMPK2, GBP4, OTOF, and SIGLEC1. The biomarker combination provided in this application can objectively and quantitatively reflect the activity of viral replication and the strength of the immune response in the patient, thereby achieving accurate assessment of the severity of viremia. This solves the problem in existing technologies that mainly rely on qualitative or semi-quantitative detection of viral nucleic acids and lack assessment methods closely related to the host's pathological state.

This invention discloses an attenuated chikungunya virus expressing a nanoluciferase gene, the nucleotide sequence of which is shown in SEQ ID NO:1. It is constructed by attenuating the virulence of the chikungunya virus LR2006-OPY1 strain by deleting 61 amino acids from positions 323 to 383 of the nsP3 protein and inserting a nanoluciferase gene after position 490 of the nsP3 protein. This virus model maintains similar growth characteristics to the wild-type virus but with significantly improved safety. Viral replication can be monitored in real time by detecting luciferase activity, making it suitable for drug screening at both cellular and animal levels. This provides an efficient and safe technical platform for the development of antiviral drugs against chikungunya virus.

The invention belongs to the field of gene engineering, and particularly relates to application of chikungunya virus structural protein in improvement of pseudovirus stability, a construction method of the chikungunya virus structural protein and vaccines, antibody evaluation and in-vivo gene therapy products. The method comprises the following steps: constructing a human codon optimized Asian strain CHIKV-E3 + E2 + 6K + E1 structural protein eukaryotic vector, and designing two types of binder expression plasmids of targeted T cells; the vector, a psPAX2 helper plasmid and a lentivirus target vector containing an SFFV promoter and a ZsGreen reporter gene (or a CAR therapeutic gene) are co-transformed into a 293T cell, and the lentivirus is prepared through culture, filtration and centrifugation. The lentivirus can efficiently infect Jurkat cells and activate human T cells, obviously reduces the infection efficiency on 293T cells so as to reduce the off-target effect, has excellent stability in human serum, and provides a safe and efficient gene delivery tool for in-vivo CAR-T therapy.

The invention features compositions and methods for the prevention or treatment of one or more strains of Chikungunya virus, as well as other alphavirus-mediated diseases.

The invention discloses a chikungunya virus monoclonal antibody and application thereof in preparation of preventive and therapeutic antibody drugs, and belongs to the technical field of medicines. The chikungunya virus envelope protein E2 expressed by human embryo kidney 293 cells is used as an antigen to immunize a rabbit, B cells capable of being specifically combined with the chikungunya virus envelope protein E2 are screened from rabbit spleen cells through flow sorting, and signal peptide and variable region gene fragments of an antibody are cloned through reverse transcription-polymerase chain reaction. According to the present invention, the chikungunya virus-resistant monoclonal antibody with high neutralizing activity and capable of 100% protection of mice against chikungunya virus lethal attack is obtained by carrying out enzyme-linked immunosorbent assay, in-vitro virus neutralization and mouse toxicity attack experiment after mammalian cell expression and purification, and the recombinant chikungunya virus-resistant monoclonal antibody has characteristics of high neutralizing activity and high immunogenicity, and can be used for preparing the chikungunya virus-resistant monoclonal antibody, and the recombinant chikungunya virus-resistant monoclonal antibody. The monoclonal antibody has application value in prevention and treatment of yellow fever.

The invention relates to a kit capable of simultaneously detecting chikungunya virus (CHIKV), dengue virus (DENV), Sindbis virus (SINV) and Japanese encephalitis virus (JEV). The kit comprises a primer pair I for detecting CHIKV, a primer pair II for detecting DENV, a primer pair III for detecting SINV and a primer pair IV for detecting JEV. The kit disclosed by the invention can be used for simultaneously carrying out one-step fluorescent quantitative PCR detection on CHIKV, DENV, SINV and JEV, the sensitivity and the specificity of the kit are high, and stable and effective fluorescent signals can be obtained when the copy number of fragments in a detection sample reaches 250 copies / mL.

This invention provides a detection reagent for chikungunya virus nucleic acid genotyping and its application. Three sets of specific primers and probes are designed for the three genotypes of chikungunya virus, effectively avoiding cross-interference and improving detection accuracy. The PCR reaction solution, enzyme solution, and primers / probes are premixed to achieve rapid detection in a single tube. Furthermore, by optimizing the PCR reaction solution formulation and adding diatomaceous earth nanoparticles and NP-40, the stability degradation after premixing the reaction solution and enzyme solution is overcome, allowing the fully premixed system to be stably stored, significantly extending the reagent's shelf life and amplification efficiency.

The present invention relates to compounds for use in the treatment of a disease or condition caused by Zika virus, Dengue virus, West Nile virus, Chikungunya virus, O`nyong`nyong virus, Sindbis virus or SARS-CoV-2 virus.

The application discloses a multiplex qPCR primer probe set, a kit, a detection method and application for detecting alphaviruses, and belongs to the technical field of molecular biological detection. The application designs a set of primer probe combination for a plurality of alphaviruses capable of infecting insect cell lines, including western equine encephalitis virus, eastern equine encephalitis virus, sindbis virus, chikungunya virus, AURA virus and Venezuelan equine encephalitis virus. The combination realizes synchronous detection and identification of a plurality of target viruses in one reaction system. The application also provides a kit containing the primer probe set and a corresponding detection method. The detection method has the advantages of wide coverage, high detection sensitivity, strong specificity, good anti-matrix interference capability and the like, and is suitable for safety detection and quality control of alphavirus contamination in insect cell banks, cell cultures and related biological products.

This invention belongs to the fields of molecular virology and immunology, and provides an alpaca-derived nanobody that specifically binds to Chikungunya virus (CHIKV), its preparation method, and its applications. The nanobody has a heavy chain variable region (VHH), which comprises the following CDRs: CDR1 (amino acid sequence as shown in SEQ ID NO:1), CDR2 (amino acid sequence as shown in SEQ ID NO:2), and CDR3 (amino acid sequence as shown in SEQ ID NO:3). The VHH includes four frame regions FR1-FR4; FR1, FR2, FR3, and FR4 are arranged alternately with CDR1, CDR2, and CDR3 in sequence. The nanobody of this invention can efficiently neutralize CHIKV virus and inhibit its infection, and has the potential to prepare drugs or kits for the prevention, treatment, and / or detection of CHIKV infection. The nanobody of this invention can bind with high affinity to the E protein of CHIKV, effectively inhibiting CHIKV pseudovirus infection.

The invention relates to the field of biological detection, in particular to a primer, a probe, a detection method and a kit aiming at chikungunya virus. The primer pair and the probe take the conserved sequence of the chikungunya virus nsP1 gene as a target, are suitable for detecting the chikungunya virus through an RT-RPA-LFD method, and can realize accurate, rapid and efficient detection of the chikungunya virus.

The application discloses a carbon-coated zirconium oxide composite material, a colorimetric / photothermal dual-mode signal nano probe and application thereof in rapid quantitative detection of chikungunya virus. The colorimetric / photothermal dual-mode signal nano probe is formed by coupling a carbon-coated zirconium oxide composite nano material obtained by calcining mesoporous UiO-66 in an inert atmosphere with a chikungunya virus E2 protein monoclonal antibody. In a specific application, a chromatography test strip is constructed based on the colorimetric / photothermal dual-mode signal nano probe. The chromatography test strip comprises a nitrocellulose membrane provided with a T line and a C line. During detection, a sample and the nano probe form an immune complex and generate a colorimetric signal visible to the naked eye at the T line, and meanwhile, under the irradiation of 808 nm near-infrared laser, a temperature rise Delta T related to the concentration of a target object is generated at the T line, so that on-site rapid screening and photothermal quantitative review are realized. The chromatography test strip has both simple operation and reliable quantification, and has stronger anti-interference ability in a complex biological matrix, and is suitable for instant detection of chikungunya virus.

The invention discloses a chikungunya virus envelope E2 protein monoclonal antibody and application of the chikungunya virus envelope E2 protein monoclonal antibody in preparation of preventive and therapeutic antibody drugs, and belongs to the technical field of medicines. The chikungunya virus envelope protein E2 expressed by human embryo kidney 293 cells is used as an antigen to immunize a rabbit, B cells capable of being specifically combined with the chikungunya virus envelope protein E2 are screened from rabbit spleen cells through flow sorting, and signal peptide and variable region gene fragments of an antibody are cloned through reverse transcription-polymerase chain reaction. According to the present invention, the chikungunya virus-resistant monoclonal antibody with high neutralizing activity and capable of 100% protection of mice against chikungunya virus lethal attack is obtained by carrying out enzyme-linked immunosorbent assay, in-vitro virus neutralization and mouse toxicity attack experiment after mammalian cell expression and purification, and the recombinant chikungunya virus-resistant monoclonal antibody has characteristics of high neutralizing activity and high immunogenicity, and can be used for preparing the chikungunya virus-resistant monoclonal antibody, and the recombinant chikungunya virus-resistant monoclonal antibody. The monoclonal antibody has application value in prevention and treatment of yellow fever.

Compositions, methods and kits for detecting Chikungunya virus (CHIKV) nucleic acids are for detecting very low levels of the viral nucleic acids using nucleic acid amplification. The kit includes a first primer up to 100 bases long and includes a target-complementary 3′ terminal sequence of 15-48 contiguous bases. The first primer optionally may include a first primer 5′ sequence (i.e., an upstream sequence) that is not complementary to CHIKV nucleic acids.

The invention belongs to the technical field of biology, and particularly discloses a cell line capable of stably expressing an nsP4 gene and application of the cell line in preparation of a replication-deficient chikungunya virus. The inventor uses retrovirus for expressing CHIKV nsP4 to infect hamster kidney cells (hamster kidney cells), after puromycin screening, verification of passage stability of monoclonal cells, protein expression stability, replication-deficient virus titer and the like is carried out, finally, a cell line which can be used for continuous passage of CHIKV replication-deficient viruses and has high titer is obtained, and the preservation number is CCTCC NO: C2025281. The replication-deficient virus CHIKV-delta nsP4 generated by the RNA of the nsP4 gene deleted from the trans-complementary CHIKV of the cell line has good safety, immunogenicity and immune protection efficacy, can effectively resist the challenge infection of wild viruses, and can be used for preparing a safe and effective CHIKV novel vaccine candidate strain.

The invention provides a chikungunya virus invasion model, an establishment method and application, according to the invasion model, chikungunya structural protein expression plasmids and firefly luciferase reporter gene plasmids containing specific packaging signals are co-transfected to mammalian cells, and the chikungunya structural protein expression plasmids and the firefly luciferase reporter gene plasmids containing the specific packaging signals are co-transfected by utilizing a packaging mechanism of the packaging signals. And self-assembling to form the high-simulation virus-like particle capable of efficiently bearing the reporter gene. According to the method, evaluation of chikungunya virus invading cells without depending on a BSL-3 experimental environment is achieved, and drugs / vaccines for resisting the chikungunya virus can be quantitatively screened through firefly luciferase. The method has the advantages that the whole process that viruses invade host cells can be efficiently and accurately simulated, meanwhile, high sensitivity and operation convenience are achieved, and a stable, reliable and high-drug-effect-resolution experimental platform is provided for deeply researching the invasion mechanism of CHIKV and developing targeted inhibitor high-throughput screening.

The present invention relates to a multiplex and simultaneous antigen detection kit (200) for the rapid diagnosis of Dengue, Chikungunya, and two forms of Malaria (Plasmodium vivax and Plasmodium falciparum) from whole blood samples. Utilizing vertical flow technology, the kit allows the detection of multiple antigens concurrently, offering faster results with enhanced sensitivity and specificity compared to traditional lateral flow assays. The diagnostic device employs metal nanoparticles and gold conjugates to detect the specific antigens, facilitating co-infection detection without the need for serum or plasma separation.

The present invention concerns antibodies and antigen-binding fragments of antibodies which specifically bind to and neutralize Chikungunya virus (CHIKV) and which are engineered to develop therapeutics in order to treat CHIKV disease or prevent CHIKV infection. The invention also relates to pharmaceutical compositions comprising antibodies of the invention and the use of the antibodies for the prevention and treatment of CHIKV disease.

Synthetic immunogenic polypeptides based on a curated set of natural alphavirus structural protein sequences are described. The polypeptides were computationally designed to provide optimal coverage of potential immunogenic epitopes of wild-type alphaviruses, including isolates of Venezuelan equine encephalitis virus, Western equine encephalitis virus, Eastern equine encephalitis virus and Chikungunya virus. Sets of immunogenic polypeptides, as well as nucleic acid molecules and vectors encoding the immunogenic polypeptides are also described. The disclosed compositions can be used to elicit an immune response against alphaviruses in a subject.

To provide an antibody that neutralizes Chikungunya virus (CHIKV) and is suitable for prophylactic and therapeutic use against CHIKV, and also to provide pharmaceutical compositions comprising the antibody and the use of the antibody for the prevention and treatment of CHIKV disease.SOLUTION: The present invention provides an isolated monoclonal antibody that binds to CHIKV and comprises three heavy chain complementarity determining regions (CDRHs) and three light chain complementarity determining regions (CDRLs), where the CDRHs and the CDRLs have specific amino acid sequences.SELECTED DRAWING: None